PGxCardio™ is a pharmacogenomics test that helps predict how a patient will respond to cardiac drug therapy based on their individual genetic background, which can affect drug absorption, metabolism, and activity.
This test can be ordered by itself or paired with the AtheroGxOne™ and CardioGxOne™ as a reflex test based on results, providing essential information to help guide effective treatment decisions and potentially reduce adverse drug events.
Genes included: ABCB1 • ACE • ADRA2A • AGTR1 • APOE • CYP2C19 • CYP2C9 • CYPD26 • CYP3A4 • CYP3A5 • CYP4F2 • KIF6 • NAT1 • NOS1AP • SLCO1B1 • VKORC1
It is a pharmacogenomics test to better treat Cardiovascular diseases and Conditions
16 Pharmacogenomics genes assayed
17 Drug classes covered
62 Cardiovascular drugs included
Cutting Edge Technology
Advanced Next-Generation sequencing technology and propriety bioinformatics analysis.
Categorizes drug recommendations specific to the patient’s diagnosis and current medications in four quadrants.
- Acute Coronary Syndrome (ACS)
- Angina Pectoris
- Atrial Fibrillation (AFIB)
- Cerebrovascular Disease (Stroke)
- Chronic Ischemic Heart Disease (IHD)
- Coronary Heart Diseases (CHD)
- Heart Failure (HF)
- Peripheral Vascular Disease (PVD)
- Thromboembolic Disorders
- Ventricular Fibrillation (VF)
- Ventricular Tachycardia (VT)
Drug Classes Covered
- ACE Inhibitors
- Angiotensin II Receptor Blockers
- Antianginal Drugs
- Antiarrhythmic Drugs
- Beta Blockers
- Calcium Channel Blockers
- Phosphodiesterase Inhibitors
- Antilipemic Agents